Marta Hergueta-Redondo
Marta Hergueta-Redondo has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Damarys Loew
Institut Curie, PSL Research University, CurieCoreTech Mass Spectrometry Proteomics, Paris, France
1 shared publication - Florent Dingli
Institut Curie, PSL Research University, CurieCoreTech Mass Spectrometry Proteomics, Paris, France
1 shared publication - Gisela D'ANgelo
Institut Curie, CNRS UMR144, Structure et Compartiments Membranaires, Université Paris Sciences et Lettres, Paris, France
1 shared publication - Graça Raposo
Institut Curie, PSL University, Sorbonne Université, CNRS UMR144, Cell Biology and Cancer, Structure and Membrane Compartments, Paris, France
1 shared publication - Héctor Peinado
Spanish National Cancer Research Center (CNIO)
1 shared publication - Lorena Martin-Jaular
INSERM U932 Institut Curie Research Center PSL Research University Paris France
1 shared publication
Latest Publications
- Open Access
CD133 shapes extracellular vesicle cargo and angiogenic function in basal-like triple-negative breast cancer
Extracellular vesicles (EVs) are central mediators of tumor-stroma communication, yet the mechanisms governing their biogenesis and functional cargo remain poorly understood. Here, we identify CD133 (Prominin-1), selectively expressed in basal-like triple-negative breast cancer (BL-TNBC) cells, as a key regulator of EV production and cargo composition. CD133 localizes to plasma membrane protrusions and lipid rafts, maintaining membrane architecture, promoting EV release, and shaping selective protein loading, including the pro-angiogenic factor CD105. Functionally, CD133⁺ EVs potently induce endothelial tubulogenesis in a CD105-dependent manner, independently of EV uptake or endothelial proliferation. In vivo , these EVs preferentially accumulate in the lung and liver, highlighting organ-specific communication. Mechanistically, CD133 maintains lipid raft integrity, facilitating CD105 selective incorporation into vesicles, thereby establishing a spatially coordinated CD133-CD105 axis. Together, our findings define a subtype-specific EV population whose identity and angiogenic activity are dictated by membrane organization. By linking protrusion architecture to vesicle-mediated signaling, this study highlights CD133-enriched EVs as potential biomarkers and therapeutic targets in aggressive BL-TNBC.
Open AccessCD133 shapes extracellular vesicle cargo and angiogenic function in basal-like triple-negative breast cancer
Extracellular vesicles (EVs) are central mediators of tumor-stroma communication, yet the mechanisms governing their biogenesis and functional cargo remain poorly understood. Here, we identify CD133 (Prominin-1), selectively expressed in basal-like triple-negative breast cancer (BL-TNBC) cells, as a key regulator of EV production and cargo composition. CD133 localizes to plasma membrane protrusions and lipid rafts, maintaining membrane architecture, promoting EV release, and shaping selective protein loading, including the pro-angiogenic factor CD105. Functionally, CD133⁺ EVs potently induce endothelial tubulogenesis in a CD105-dependent manner, independently of EV uptake or endothelial proliferation. In vivo , these EVs preferentially accumulate in the lung and liver, highlighting organ-specific communication. Mechanistically, CD133 maintains lipid raft integrity, facilitating CD105 selective incorporation into vesicles, thereby establishing a spatially coordinated CD133-CD105 axis. Together, our findings define a subtype-specific EV population whose identity and angiogenic activity are dictated by membrane organization. By linking protrusion architecture to vesicle-mediated signaling, this study highlights CD133-enriched EVs as potential biomarkers and therapeutic targets in aggressive BL-TNBC.